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Introduction
Simple method of obtaining polyester micro- and nanospheres
Encapsulation of medicaments within polymer matrix
Structural characteristics, morphology, stability
In vitro degradation and release tests
Antimicrobial activity
The cytotoxicity of  nanoparticles with human hepatoma cell lines
Induction of intracellular reactive oxygen species
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• Controlled drug delivery
• Biomacromolecules
– biocompatible, immunocompatible, readily eliminated from 
the body, preferably through biodegradation.
– natural and synthetic, based on their origin
• Aliphatic polyesters can be considered as representatives of 
synthetic biodegradable polymers.
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Introduction
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Ascorbic acid is very unstable in air, light, heat, 
moisture, presence of metal ions, oxygen, and base, and 
it easily decomposes into biologically inactive 
compounds. 
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Among promising nanomaterials with antibacterial
and antiviral properties are metallic nanoparticles (Rochelle
RA et al, Chem Soc Rev 2012;41:2943–70)
Concerns related to 
• free silver ions in AgNp preparations 
• nanoparticles’ bare metallic surface, (Beer C, et al. 
Toxicol Lett 2012;208(3):286–92.)
Multifunctional PLGA particles containing poly (L-glutamic 
acid)-capped silver nanoparticles and ascorbic acid -
PLGA/AgNpPGA/AscH particles
PLGA/AgNpPGA/AscH particles - system with concurrent antioxidative and
prolonged antimicrobial activity
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UV–Vis spectra of bare and PGA-capped silver nanoparticles 
recorded immediately after preparation, and Digital photo 
showing volumetric flasks containing the negative control (A), 
bare (B) and capped silver nanoparticles (C).
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Morphology studies
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AgNpPGA 44.9 ± 5.0 0.206 -43.7 ± 12.0
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UV-Vis / physiological solution / 90 days 
The amount of silver nanoparticles that was released from the PLGA particles during the first two 
weeks was 3.4% wt and the amount of ascorbic acid was 4.1% wt. The entire amount of ascorbic 
acid has been released in 68 days of the degradation and the entire amount of silver nanoparticles 
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(a) Schematic of the experiment. (b, c) Minimal 
inhibitory concentrations of AgNpPGAs determined 
using a broth microdilution assay as a function of time, 















Determining cytotoxicity of PLGA/AgNpPGA/AscH
- MTT assay
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Determining intracellular reactive oxygen species 
formation – DCFH-DA assay
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PLGA/AgNpPGA/AscH particles are spherical, uniform and do not agglomerate.
The degradation of these particles within the physiological solution have been tracked during the 
90days and it has been determined that particles completely degrades within this period fully 
releasing all encapsulated AgNpPGA as well as ascorbic acid. 
PLGA/AgNpPGA/AscH particles did not affect the viability of HepG2 cells, they diminished 
the ROS generation and moreover showed superior and extended antimicrobial activity
towards the Gram-positive bacteria methicillin-resistant Staphylococcus aureus (MRSA; ATCC 
43300),and the Gram-negative bacteria Escherichia coli (ATCC 25922). 
Our data suggest that antioxidative and, at the same time, antimicrobial agent, biodegradable 
PLGA/AgNpPGA/AscH particles, PLGA/AgNpPGA/AscH are potential candidate for use in 
pharmaceutical products and medical devices that may help to prevent the infections and 
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INSTITUTE OF TECHNICAL SCIENCES 
OF THE SERBIAN ACADEMY OF 
SCIENCES AND ARTS
Equipment
FTIR spectroscopy, Uv-Vis spectroscopy, thermal analysis (DSC131 EVO, 
-170 to 700 °C; SETSYS TMA, up to 2400 °C, SETSYS TG-DTA/DSC, up 
to 2400 °C) mass spectrometer Omnistar GSD 320, XRD Philips PW1050, 
optical microscopy, particle analyzer. 
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Main activities of the department
Fine particles processing and nanotechnologies, drug delivery, colloids, 
polyesters, poly(lactide-co-glycolide), poly(e-caprolactone), micro and 
nanospheres, bioactive glass, scaffolds, biomacromolecules, polymers, 
structure-property relationships of polymers, silver, selenium 
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Thank you for your attention!
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